PET-MRI Doctors in Turkey — Page 2

Dr. Mehmet Ali Gok is an Associate Professor of General Surgery at Medipol University Pendik Hospital. He specializes in laparoscopic hernia repair and metabolic surgery. Dr. Gok has authored over 20 national and international scientific articles on surgical outcomes. He practices at a hospital with 95.4 out of 96.4 healthcare quality points.

• Certified in robotic colorectal surgery and laparoscopic hernia techniques on cadavers.
• Received specialized training from the European Hernia Society in Dubai.
• Served as a former Chief Physician at Silopi State Hospital.
• Editor of several medical books on oncological, hernia, and minimal invasive surgery.

Specializations

Abdomen Radiology

Doppler Radiology

Obstetric Radiology

Breast Radiology

Musculoskeletal Radiology

Pediatric Radiology

Neuroradiology

Nonvascular Interventional Procedures

Dr. Erkan Karatas is an ENT and maxillofacial surgeon at Atlas University Hospital in Istanbul. He specializes in skull base surgery and cochlear implant placement. Dr. Karatas has contributed to over 100 medical articles. He completed specialized training at prestigious centers in the US, Germany, Italy, and Switzerland.

• Member of 11 professional associations, including the American Academy of Otolaryngology.
• Expert in complex surgeries for thyroid, tongue, and larynx cancers.
• Performs specialized procedures like stapedectomy, tympanoplasty, and orthognathic surgery.
• Works at an AACI-accredited hospital that treats 565,000 patients annually.

Academic Details

Faculty / University
19 Mayis University, Faculty of Medicine, Samsun – Turkey

Date of Graduation
1992

Postgraduate Training
Institution: Department of Radiology, Faculty of Medicine, Erciyes University, Kayseri – Turkey
Supervisor in Charge of Training: Mustafa Ozturk
Training Period: From 1993 to 1998
Title of Thesis: Evaluation of Lower Extremity Artery-Occlusive Disease by MR Angiography

Accreditation

Radiology Specialist: 1998, The Ministry of Health of Turkey

Associate Professor: 2003, Interuniversity Committee

Academic Experience

Residency: Department of Radiology, Erciyes University, Kayseri – Turkey (1993 to 1998)

Private Practice: Maternal and Children Hospital, Sivas – Turkey (1998–2000)

Academic Positions:

2000 to 2003: Assistant Professor of Radiology, Firat University, Elazig – Turkey

2003 to 2009: Associate Professor of Radiology, Firat University, Elazig – Turkey

2009 to 2010: Professor of Radiology, Firat University, Elazig – Turkey

2010 to 2015: Professor of Radiology, Chairman, Bezmialem Vakif University, Istanbul – Turkey

2015 to 2016: Professor of Radiology, Chairman, Yeditepe University, Istanbul – Turkey

2017 to Present: Professor of Radiology, Interventional Radiology Unit, Bahçelievler Medical Park Hospital, Altınbaş University, Istanbul – Turkey

Fellowship

Institution: Department of Radiology, University Hospital of Cleveland, Case Western Reserve University, Cleveland, Ohio, USA

Duration:  2004 to 2005

Position: Research Fellow – Ultrasound & CT (Body)

Professional Memberships

-Turkish Society of Radiology

-Medical Ultrasound Society of Turkey

-Turkish Society of Radiology, Abdominal Radiology Study Group

-ESGAR – European Society of Gastrointestinal and Abdominal Radiology (Fellow)

-ESUR – European Society of Urogenital Radiology (Fellow)

-ESR – European Society of Radiology

-Turkish Society of Magnetic Resonance

-Turkish Society of Radiology, Urogenital Radiology Study Group

-Turkish Society of Interventional Radiology

-Korean Society of Radiology (International Member)

-Radiological Society of North America (RSNA) – Corresponding Member

Prizes and Awards

European Congress of Radiology (ECR) 2002, Vienna – Image Interpretation, 3rd Prize

Interpretation Corner of European Radiology 2003 – 2nd Prize

Cases of the Day – ESGAR 2007, Lisbon, Portugal – 2nd Prize

Cases of the Day – ESGAR 2009, Valencia, Spain – 1st Prize

Dr. Cevdet Gokcek is a neurosurgeon at Medipol University Pendik Hospital in Istanbul. He specializes in brain, spine, and pediatric nerve conditions. He has treated thousands of patients for complex disorders. Dr. Gokcek is a member of the Turkish Neurosurgical Society. He previously completed a microsurgery course at Hacettepe University.

• Achieved a 95% success rate for severe brain and spine surgeries.
• Performs transnasal pituitary tumor removals and endoscopic skull base procedures.
• Authored 17 articles published in national and international medical journals.
• Completed a neuro-endoscopy workshop at Ghent University in Belgium.

Dr. Tuncay Tas is a urological surgeon at Safe Urology Clinic in Istanbul. He is one of the first five doctors globally to publish results on P-Shot applications. Dr. Tas specializes in urological oncology and male sexual health. He completed his fellowship at Heidelberg University in Germany. His practice focuses on regenerative medicine and robotic surgery for cancer.

• Developed a surgical technique for penile enhancement with a UK-based certification.
• Introduced combined PRP and stem cell penile injections to Turkey.
• Performs robotic prostatectomies and kidney-sparing surgeries.
• Member of the International Society for Stem Cells Applications.

Education

• Faculty of Medicine: Trakya University, 1982-1988
• Radiation Oncology Residency: Şişli Etfal Training and Research Hospital, 1994-1998
• Radiation Oncology Residency: Princess Margaret Hospital Toronto, 1996
• Phytotherapy Master's Degree: Istanbul University Faculty of Pharmacy, 2017-2018

Experience

• Professor, Head of Department: Health Sciences University Bursa Faculty of Medicine, Department of Radiation Oncology, 2021-2024
• Professor, Head of Department: Health Sciences University Izmir Faculty of Medicine, Department of Radiation Oncology, 2021-2024
• Professor: Department of Radiation Oncology, Health Sciences University Istanbul Hamidiye Faculty of Medicine, 2021-2024
• Lecturer Gelisim University SMYO, 2013-2020

Medical Interests

• Breast Cancer / Intraoperative Radiotherapy
• Gynaecological Cancers / Brachytherapy Applications
• Gastrointestinal System Tumours
• Prostate Cancer / Hydrogel Space Oar Certificate and Application
• Lung Cancers
• Brain Tumours
• Head and Neck Cancers

Areas of Interests

• Breast cancer
• Lung cancer
• Colorectal cancers
• Gynecological and urogenital cancers
• Molecular Oncology

Education:

• Kızıltepe Anatolian High School 2001
• Dicle University Faculty of Medicine 2007
• Istanbul Medeniyet University Göztepe Training and Research Hospital 2014
• Kartal City Hospital 2021
• Associate Professor of Medical Oncology 2023

Experience:

• Liv Hospital Ulus
• Adıyaman University Training and Research Hospital
• Istanbul Umraniye Training and Research Hospital
• Istanbul Umraniye Training and Research Hospital

Research:

• Phase II, Randomized, Open-Label, Multicenter Study to Comparatively Evaluate the Efficacy and Safety of GDC-9545 and Physician-Preferred Endocrine Monotherapy in Previously Treated, Estrogen Receptor Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer Patients, Other ( International), Dr. Murat Ayhan
• Phase III, Randomized, Evaluating the Efficacy and Safety of Palbociclib and Fulvestrant with Gdc-0077 Compared with Placebo in Patients with Pik3ca-Mutant, Hormone Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer. Double Blind, Placebo Controlled Study, Other (International), Dr. Murat Ayhan
• Randomized, Multicenter, Phase Ib/III Study Evaluating the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Atezolizumab Compared to Intravenous Atezolizumab in Patients with Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer, Other (International) Dr. Murat Ayhan
• Randomized, Controlled, Multicenter, Open-Label Study Including Observation Follow-Up for PSMA-PET-Negative Patients, Investigating the Efficacy and Safety of Addition of Apalutamide to Radiotherapy and LHRH Agonist in PSMA-PET-Positive High-Risk Hormone-Sensitive Prostate Cancer Patients, Other (International) Dr. Murat Ayhan
• Biomarker Study to Identify Patients with Advanced Stage Urothelial Cancer and Fibroblast Growth Factor Receptor Gene Aberrations-42756493BLC0002, Other (International), Dr. Murat Ayhan
• Publications:
• Ayhan M, Turan N, Köstek O, et all. Does the efficacy of regorafenib differ in chemotherapy refractory metastatic colorectal cancer patients who had mucinous pathology compared to those who had non-mucinous pathology? Curr Probl Cancer. 2021 Jun;45(3):100670. doi: 10.1016/j.currproblcancer.2020.100670.
• Ayhan M, Odabas H, Turan N, et all. Factors affecting the mortality rate of patients with cancer hospitalized with COVID-19: a single center's experience. J Chemother. 2021 Nov;33(7):499-508. doi: 10.1080/1120009X.2021.1923153.
• Ayhan M, Laçin Ş, Özyükseler DT, et all. Does systemic anti-tumor therapy increase COVID-19 risk in patients with cancer? J Oncol Pharm Pract. 2021 Sep;27(6):1461-1467. doi: 10.1177/10781552211015762.
• Ayhan M, Abamor E, Coban Kokten S, et al. Value of FDG PET/CT in Predicting Pathologic Complete Response After Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer. EJMI 2022;6(2):165–175.
• Ayhan M, Terzioglu K. Experience With Rapid Drug Desensitization With Chemotherapeutics; A SingleCentre Retrospective Study. EJMI 2021;5(3):380–387.
• Doğan A, AYHAN M. Survival analysis of patients with triple-negative breast cancer: a single-center experience. Journal of Oncological Sciences, 8(2), 94-99., Doi: 10.37047/jos.2022-89749
• Terzioğlu K, Ayhan M. Comparative Assessment of Platinum Salts and Taxane Group Hypersensitivity Reactions, The Role of Skin Tests in Diagnosis? J Oncol Pharm Pract. 2021 Nov 30:10781552211050084. doi: 10.1177/10781552211050084.
• Tacar SY, Selcukbiricik F, Yilmaz M, Erturk K, Murat Sarici A, Gulturk I, Ayhan M, Tural D. Nivolumab for metastatic uveal melanoma: a multicenter, retrospective study. Melanoma Res. 2021 Oct 1;31(5):449-455. doi: 10.1097/CMR.0000000000000744.
• Özyurt E, Özçelik S, Sürmeli H, Çelik M, Ayhan M, Özçelik M. Side effects of immune-checkpoint inhibitors: Can multiple side effects be seen in a patient? J Oncol Pharm Pract. 2022 Mar;28(2):462-465. doi: 10.1177/10781552211038136.
• Dülgar Ö, Öven BB, Atcı MM, Arıkan R, Ay S, Ayhan M, Selvi O, Ozyukseler DT, Bayram E, Özcan E, Yasin Aİ, Gümüş M. Is the benefit of using adjuvant capecitabine in patients with residual triple-negative breast cancer related to pathological response to neoadjuvant chemotherapy? Expert Rev Anticancer Ther. 2022 Jul;22(7):773-780. doi: 10.1080/14737140.2022.2076670.
• Hizal M, Bilgin B, Paksoy N, Ayhan M, et all. The real-life efficacy and safety of osimertinib in pretreated advanced non-small cell lung cancer patients with T790M mutation: a Turkish Oncology Group Study. J Cancer Res Clin Oncol. 2022 Jun;148(6):1501-1508. doi: 10.1007/s00432-021-03748-7.
• Volume I, Kucukarda A, Atcı MM, Ayhan M, et all. Efficacy and safety of trastuzumab emtansine in older patients with HER2-positive advanced breast cancer: a real-world study. Tumori. 2022 Feb;108(1):19-25. doi: 10.1177/03008916211037739.
• Dogan I, Ayhan M, Gurbuz M, et all. The frequency and prognostic significance of ABO/Rh blood groups in male breast cancer patients: A multicenter study. Medicine (Baltimore). 2022 Sep 2;101(35):e30147. doi: 10.1097/MD.0000000000030147.
• Ozcelik M, Oyman A, Cil I, Duzgun O, Ozkan OF, Ayhan M. Cytoreductive Surgery versus Systemic Chemotherapy alone in Isolated Peritoneal Carcinomatosis of Colorectal Origin. J Coll Physicians Surg Pak. 2021 Nov;31(11):1308-1313. doi: 10.29271/jcpsp.2021.11.1308.
• Başoğlu T, Sakin A, Erol C, Ayhan M, et all. Real life experienceof patients with locally advanced gastric and gastroesophageal junction adenocarcinoma treated with neoadjuvant chemotherapy: a Turkish oncology group study. J Chemother. 2022 May 17:1-8. doi: 10.1080/1120009X.2022.2073159.
• Özdemir Ö, Zengel B, Yildiz Y, Ayhan M, et all. The effectiveness and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early-stage human epidermal growth factor receptor 2-positive breast cancer: Turkish Oncology Group study. Anticancer Drugs. 2022 Aug 1;33(7):663-670. doi: 10.1097/CAD.0000000000001310.
• Hizal M, Bilgin B, Paksoy N, Ayhan M, et all. The percentage of ALK-positive cells and the efficacy of first-line alectinib in advanced non-small cell lung cancer: is it a novel factor for stratification? (Turkish Oncology Group Study). J Cancer Res Clin Oncol. 2022 Sep 1. doi: 10.1007/s00432-022-04252-2.
• Hizal M, Bilgin B, Paksoy N, Ayhan M, et all. Real-world data on efficacy and safety of first-line alectinib treatment in advanced-stage, ALK-positive non-small-cell lung cancer patients: a Turkish Oncology Group study. Future Oncol. 2022 Jul;18(23):2573-2582. doi: 10.2217/fon-2022-0083.
• Topcu A, Atci MM, Secmeler S, Besiroglu M, Ayhan M, Ozkan M, Bozkurt O, Urakci Z, Ay S, Geredeli C, Yasin AI, Turk HM. Efficacy of trastuzumab and potential risk factors on survival in patients with HER2-positive metastatic gastric cancer. Future Oncol. 2021 Nov;17(31):4157-4169. doi: 10.2217/fon-2021-0398.
• Bilgin B, Sendur MAN, Yucel S, Ayhan M, et all. Real-life comparison of the afatinib and first-generation tyrosine kinase inhibitors in nonsmall cell lung cancer harboring EGFR exon 19 deletion: a Turk Oncology Group (TOG) study. J Cancer Res Clin Oncol. 2021 Jul;147(7):2145-2152. doi: 10.1007/s00432-020-03501-6.
• Atci MM, Akagunduz B, Demir M, Arikan R, Ay S, Ozer M, Ayhan M, Cil I, Demir N, Ozyurt N, Karakaya G, Cevik GT, Onder AH, Selvi O, Sakin A. The impact of adjuvant oxaliplatin and tumor sidedness on the overall survival of stage IIB colon cancer patients: a multicentre study. J Chemother. 2023 Feb;35(1):19-28. doi: 10.1080/1120009X.2022.2040770.
• Tataroglu Ozyukseler D, Ay S, Turan M, Alkan G, Ayhan M, Surmeli H, et al. The Systemic Inflammation Response Index as a Prognostic Marker in Advanced Pancreatic Cancer. EJMI 2022;6(3):367–373.
• Yıldız F, Ayhan M, Demir H, et all. Comparing the efficacy of cabazitaxel in secondline and third-Line treatment of metastatic castration-resistant prostate cancer: a multi-center experience from Turkey. International Journal of Contemporary Medical Research, 7(9), 112-116.,Doi: 10.21276/ijcmr.2020.7.9.30
• Terzioğlu K, Ayhan M. Distribution of allergens detected on patch tests of patients with allergic contact dermatitis and investigation of their atopic background. Annals of Medical Research, 29(5), 422-426., doi: 10.5455/annalsmedres.2021.07.490
• Arikan R, Atci MM, Ay S, Ayhan M, et all Prognostic significance of mucinous histology in left sided metastatic colorectal cancers with wild type RAS and evaluation of backbone chemotherapy regimens. Oncol Lett. 2023 Apr 5;25(5):208. doi: 10.3892/ol.2023.13795.
• Almuradova E, Yalcin S, Arıkan R, Ayhan M, Demir H, Cevik GT, Karaca M, Petekkaya I, Karabulut B. Survival of Patients With Metastatic Rectum Cancer Who Underwent Metastasectomy Following Conversion Chemotherapy Sans Pelvic Radiotherapy: A Turkish Oncology Group Study. Cureus 2023 May 17;15(5):e39119. doi: 10.7759/cureus.39119.
• Topcu A, Besiroglu M, Atci MM, Ayhan M, et all. Second-line Therapy after Trastuzumab Failure in HER2-Positive Metastatic Gastric Cancer: A Real-life Data. EJMI 2023;7(2):153–161. DOI: 10.14744/ejmi.2023.22720
• Book Writing:
• Drug interactions and side effects of targeted agents, Section name: (Small molecule tyrosine kinase inhibitors; ROS-1 targeted therapies (Crizotinib, Seritinib)) (2021)., AYHAN MURAT, Turkish Clinics Journal of Medical Sciences, Editor: Mehmet Aliustaoglu, Publishing number:1, Number of Pages 92, ISBN:978-625-401- 466-6, Turkish
• Approach to gastrointestinal stromal tumors and neuroendocrine tumors, Department name: (Medical approach in primary non-gastrointestinal neuroendocrine tumors) (2020)., AYHAN MURAT, Akademisyen Yayınevi, Editor: Anılır Ender, Number of editions: 1, Number of Pages 382, ISBN: 9786052585719, Turkish
• Internal medicine emergencies, Department name: (Oncological emergencies) (2022)., YILDIRIM SEDAT, AYHAN MURAT, Efe Academic Publishing, Editor: Serdar Olt, Number of editions: 1, Number of Pages 232, ISBN: 978-625-8324-66- 2, Turkish
• Physicians' chemotherapy cancer drug manual 2020, Section name: (Common chemotherapy regimens in clinical practice) (2022)., SÜMBÜL AHMET TANER, ALKAN ALI, AKSOY ASUDE, AYHAN MURAT, et all, Türkiye Klinikleri Journal of Medical Sciences, Editor: EDWAR CHU, VINCENT T. DEVITA, SAADDETIN KILIÇKAP, CEMIL BILIR, SELÇUK SEBER, Number of editions: 1, Number of pages 772, ISBN: 978-625-401-290- 7, Turkish (Book Translation)

Dr. Turkan Ozturk Topcu is a clinical oncologist at Biruni University Hospital in Istanbul. She maintains professional ties with the MD Anderson Cancer Center in the USA. She specializes in the treatment of breast, lung, and gastrointestinal cancers. Dr. Topcu is a member of both ESMO and ASCO.

• Completed a fellowship at the Sunnybrook Odette Cancer Center Breast Clinic in Canada.
• Treats a wide range of conditions including liver, pancreatic, and gynecological cancers.
• Held clinical roles at major institutions like Moffitt Cancer Center in the USA.
• Works at Biruni University Hospital, a TEMOS-accredited facility in Turkey.

Dr. Senem Karabulut is a medical oncologist at Biruni University Hospital in Istanbul. She is a professor and holds a PhD in molecular oncology. Dr. Karabulut is certified by the European Society for Medical Oncology (ESMO) Board. She previously trained as an observer at University Hospital in New Jersey, USA.

• Specializes in immunotherapy and targeted treatments for gastrointestinal and breast cancers.
• Treats hepatobiliary system tumors, lung cancer, and genitourinary malignancies.
• Qualified by the Turkish Medical Oncology Society Board Exam.
• Practices at Biruni University Hospital, a TEMOS-accredited facility.

Dr. Rafet Eren is a hematologist at Biruni University Hospital in Istanbul. He specializes in treating leukemia, lymphoma, and myeloma. Dr. Eren is an Associate Professor with around 50 scientific publications in international journals. He received the Young Researcher Award from the Turkish Society of Hematology.

• Performs bone marrow transplants and haploidentical stem cell transplantation.
• Provides CAR T-cell therapy and biological treatments for blood cancers.
• Member of the European Society of Hematology and the Turkish Hematology Association.
• Works at Biruni University Hospital, a TEMOS-accredited facility in Turkey.

Dr. Ismail Yildiz is an anesthesiologist and intensive care specialist at Biruni University Hospital. He holds a subspecialty in intensive care from Akdeniz University. Dr. Yildiz manages critical conditions including sepsis and acute respiratory distress syndrome. He works at a TEMOS-accredited facility in Istanbul equipped with 15 operating rooms.

• Expert in ECMO and renal replacement therapy for critically ill patients.
• Member of the European Society of Intensive Care Medicine.
• Specializes in organ transplant anesthesia and life support for brain death cases.
• Uses echocardiography and ultrasonography for bedside patient monitoring.

Areas of Interests

• MR Linac
• Three Dimensional Brachytherapy
• Four Dimensional (4D) Radiotherapy
• Stereotactic RT & IMRT
• Breast Cancer, Gynecological Cancers
• Head – Neck Cancers
• Urological Tumors, Gastrointestinal Cancers
• Lung Cancer
• Central Nervous System Tumors & Metastases
• Skin Cancers
• Soft Tissue Tumors

Education:

• Istinye University Medical Faculty, Professor Doctor (2017 – Continued)
• Istine University Medical Faculty Associate Professor Doctor (2016 – 2017)
• Liv Hospital Radiation Medicine Center, Tbilisi, Georgia, Radiation Oncology Consulting Docor (2016 – 2019)
• Liv Hospital, Radiation Oncology (2015 – Continued)
• Istanbul University Oncology Institution, Associate Professor (2012 – 2015)
• Stereotactic Radiotherapy, Thoracic Oncology, University of North Carolina, NC, USA (2010 – 2011)
• Kocaeli University Radiation Oncology Department, Associate Professor Assistant (2006 – 2009)
• GATA Radiation Oncology Department, Specialist Doctor, Reserve Officer (2004 – 2005)
• Istanbul University, Medical Faculty, Dr.R.A. (1999 – 2004)
• Istanbul University, Medical Faculty, Under-Graduate (1993 – 1999)
   

Experience:

• Istinye University Medical Faculty
• Liv Hospital Ulus
• Istanbul University Oncology Institution
• University of North Carolina, NC, USA
• Kocaeli University Medical Faculty
• Istanbul University, Medical Faculty

The doctor has conducted significant research on the cumulative effective dose of radiation from chest CT scans in COVID-19 patients. This work highlights the importance of adhering to guidelines to minimize unnecessary exposure, reflecting a commitment to patient safety and evidence-based practice.

Dr. Didem Tastekin is a medical oncologist at Biruni University Hospital in Istanbul. She specializes in breast and lung cancer treatment, including stage 4 cases. Dr. Tastekin received the TUBITAK Incentive Award for her work in cancer research. She is an active member of both ESMO and ASCO.

• Awarded Best Researcher of the Year at Istanbul University Oncology Institute.
• Treats complex cases at a TEMOS-accredited university hospital.
• Coordinates oncological check-ups and screenings for both men and women.
• Expert in diagnostics including PET-MRI, tumor markers, and organ biopsies.